1. Home
  2. STNG vs TERN Comparison

STNG vs TERN Comparison

Compare STNG & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scorpio Tankers Inc.

STNG

Scorpio Tankers Inc.

N/A

Current Price

$73.46

Market Cap

3.0B

ML Signal

N/A

Logo Terns Pharmaceuticals Inc.

TERN

Terns Pharmaceuticals Inc.

N/A

Current Price

$46.44

Market Cap

4.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STNG
TERN
Founded
2009
2017
Country
Monaco
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
4.8B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
STNG
TERN
Price
$73.46
$46.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
10
Target Price
$79.00
$48.60
AVG Volume (30 Days)
1.1M
1.5M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.39%
N/A
EPS Growth
N/A
11.81
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$31.62
$1.87
52 Week High
$81.85
$48.26

Technical Indicators

Market Signals
Indicator
STNG
TERN
Relative Strength Index (RSI) 54.22 77.25
Support Level $57.95 $38.99
Resistance Level $81.85 $48.26
Average True Range (ATR) 2.70 2.31
MACD -0.72 0.43
Stochastic Oscillator 23.51 92.46

Price Performance

Historical Comparison
STNG
TERN

About STNG Scorpio Tankers Inc.

Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.

About TERN Terns Pharmaceuticals Inc.

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.

Share on Social Networks: